We previously showed that a germline deletion polymorphism in the BIM gene was sufficient to mediate intrinsic resistance to TKIs in both CML and EGFR-NSCLC [1]. This evidence concerns the gene EGFR and chronic myelogenous leukemia, BCR-ABL1 positive.